|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:administered_by
|
oral tablet
|
|
gptkbp:approves
|
gptkb:FDA
|
|
gptkbp:atccode
|
L01 XE30
|
|
gptkbp:available_on
|
generic version
brand version
|
|
gptkbp:brand
|
gptkb:Tagrisso
|
|
gptkbp:casnumber
|
1421373-65-0
|
|
gptkbp:chemical_formula
|
C18 H21 N7 O3 S
|
|
gptkbp:class
|
targeted therapy
antineoplastic agent
|
|
gptkbp:clinical_trial
|
Phase III
|
|
gptkbp:clinical_use
|
combination therapy
monotherapy
|
|
gptkbp:composed_by
|
gptkb:chemical_compound
|
|
gptkbp:contraindication
|
severe hepatic impairment
hypersensitivity to osimertinib
|
|
gptkbp:developed_by
|
gptkb:Astra_Zeneca
|
|
gptkbp:discovered_by
|
gptkb:Astra_Zeneca
|
|
gptkbp:drug_interactions
|
CYP3 A4 inducers
CYP3 A4 inhibitors
|
|
gptkbp:effective_date
|
gptkb:2015
|
|
gptkbp:excretion
|
urine
feces
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Osimertinib
|
|
gptkbp:indication
|
first-line treatment
treatment of T790 M mutation-positive NSCLC
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_monitored_by
|
cardiac function
liver function tests
|
|
gptkbp:lifespan
|
48 hours
|
|
gptkbp:marketed_as
|
gptkb:European_Union
gptkb:Japan
gptkb:United_States
|
|
gptkbp:mechanism_of_action
|
EGFR tyrosine kinase inhibitor
|
|
gptkbp:metabolism
|
hepatic
|
|
gptkbp:research_areas
|
clinical trials
oncology
pharmacology
|
|
gptkbp:route_of_administration
|
oral
|
|
gptkbp:side_effect
|
fatigue
nausea
diarrhea
rash
|
|
gptkbp:targets
|
EGFR mutations
|
|
gptkbp:type_of_care
|
important for efficacy
|
|
gptkbp:used_for
|
gptkb:Oncology
|
|
gptkbp:bfsParent
|
gptkb:EMD_Serono
gptkb:Retevmo
|
|
gptkbp:bfsLayer
|
5
|